Table of Content

1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study


2 RESEARCH METHODOLOGY


3 EXECUTIVE SUMMARY


4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 More Cost Effective than a Clinical Visit
4.2.2 Increasing Prevalence of Chronic Disease and illnesses
4.3 Market Restraints
4.3.1 Stringent Regulations for Approval
4.3.2 Lack awareness and Instruction Experts in underdeveloped economies
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry


5 MARKET SEGMENTATION
5.1 By Product
5.1.1 Pen Injectors
5.1.2 Autoinjectors
5.1.3 Wearable Injectors
5.1.4 Needle-Free Injectors
5.2 By Usage
5.2.1 Disposable
5.2.2 Reusable
5.3 By Application
5.3.1 Cancer
5.3.2 Auto Immune Diseases
5.3.3 Hormonal Disorders
5.3.4 Pain Management
5.3.5 Metabolic Diseases
5.3.6 Others
5.4 Geography
5.4.1 North America
5.4.1.1 US
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 UK
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle East and Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle East and Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America


6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Becton, Dickinson and Company
6.1.2 Gerresheimer AG
6.1.3 Insulet Corporation
6.1.4 Ypsomed AG
6.1.5 Antares Pharma Inc
6.1.6 West Pharmaceutical Services
6.1.7 Consort Medical plc
6.1.8 Sensile Medical AG
6.1.9 Owen Mumford Ltd.
6.1.10 SHL Group Auto


7 MARKET OPPORTUNITIES AND FUTURE TRENDS